Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Untreated CLL
NCT04691765Phase 1Unknown
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, open-label trial of anakinra in chronic lymphocytic leukemia (CLL). Primary endpoint: Dose Limiting Toxicity at 1 year. Status: unknown.
02
Drugs
anakinra
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04691765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04691765.